A phase II trial of miltefosine in patients with cutaneous T-cell lymphoma.
A phase II trial evaluating 6% topical miltefosine solution was performed in 12 pretreated patients with cutaneous T-cell lymphoma. Miltefosine (Miltex) was administered for 8 weeks, once per day during the first week then twice every day for seven weeks. Main side effects consisted in moderate to mild pruritus or desquamation in 57 % and 50 % of patients, respectively. No systemic nor biological toxicity was observed. This treatment was administered on an outpatient basis exclusively. The overall response rate was 58 % with a median duration of response of 12 months. Miltefosine is a safe, simple and effective treatment in certain patients with cutaneous T-cell lymphoma.
Dumontet
Charles
C
Service d'Hématologie, CH Lyon-Sud, Pierre-Bénite, Laboratoire d'Hématologie, Pavillon E, Hôpital Edouard-Herriot, 5 place d'Arsonval, 69003 Lyon Cedex 03, France. charles.dumontet@chu-lyon.fr
Thomas
Luc
L
Bérard
Frédéric
F
Gimonet
Jean François
JF
Coiffier
Bertrand
B
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D010767:Phosphorylcholine; C039128:miltefosine